Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04396236
Other study ID # 16927
Secondary ID H8H-MC-LAHV2019-
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 15, 2020
Est. completion date January 31, 2025

Study information

Verified date June 2024
Source Eli Lilly and Company
Contact There will be multiple sites in this clinical trial. 1-877-CTLIL
Phone 1-317-615-4559
Email ClinicalTrials.gov@lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 1633
Est. completion date January 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility Inclusion Criteria: - Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria: - History of migraine attacks for more than 6 months - Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit - Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours - Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator - Participant must be able to swallow a tablet - For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening - Participants must weigh at least 15 kilograms (kg) Exclusion Criteria: - Participants must not be pregnant or nursing - Participants must not have any acute, serious, or unstable medical condition - Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lasmiditan
Administered orally
Placebo
Administered orally

Locations

Country Name City State
Belgium UZ Brussel Brussels Bruxelles-Capitale, Région De
Belgium UZ Gent Gent Oost-Vlaanderen
France CHU d'Amiens-Picardie - Hôpital Sud Amiens Somme
France Centre Hospitalier Universitaire Estaing Clermont-Ferrand Puy-de-Dôme
France Centre Hospitalier Intercommunal de Créteil Créteil Val-de-Marne
France Centre Hospitalier Régional Universitaire de Lille - Hôpital Roger Salengro Lille Nord-Pas-de-Calais
France Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone Marseille Bouches-du-Rhône
France Centre Hospitalier Général de Mont de Marsan - Hôpital Layné Mont-de-Marsan Landes
France Hôpital Armand Trousseau Paris
France CHU Strasbourg-Hautepierre Strasbourg Bas-Rhin
France Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan Toulouse Haute-Garonne
Germany Private Practice - Dr. Irma Schöll Bad Homburg Hessen
Germany Klinik für Kinder- und Jugendmedizin der Ruhr-Universität Bochum im St. Josef-Hospital Bochum Nordrhein-Westfalen
Germany Praxis Dr. med. Astrid Gendolla Praxis für Neurologie, Psychosomatik,Nervenheilkunde, Psychotherapieund Sp -T Essen Nordrhein-Westfalen
Germany Universitaetsklinikum Freiburg Freiburg Baden-Württemberg
India Panchshil hospital Ahmedabad Gujarat
India Artemis hospital Gurugram Haryana
India Mangala Hospital & Mangala Kidney Foundation Mangalore Karnataka
India Lillestol Research Nagpur Maharashtra
India All India Institute of Medical Sciences New Delhi Delhi
India G.B. Pant Institute of Postgraduate Medical Education & Research New Delhi Delhi
India Sir Ganga Ram Hospital New Delhi Delhi
India Deenanath Mangeshkar Hospital & Research Centre Pune Maharashtra
India Bhakti Vedanta Hospital and Research Institute Thane Maharashtra
Italy Ospedale San Paolo Bari Bari Puglia
Italy A.O.Universitaria Meyer Firenze Toscana
Italy Universita degli Studi della Campania Luigi Vanvitelli Napoli Campania
Italy Fondazione Istituto Neurologico C. Mondino Pavia
Italy Ospedale Pediatrico Bambino Gesù Roma
Italy Ospedale Filippo del Ponte Varese Varese
Japan Hiroshima City Hospital Hiroshima
Japan Tanaka Neurosurgical Clinic Kagoshima
Japan Nagaseki Headache Clinic Kai Yamanashi
Japan Kanagawa cancer center Kiryu Gunma
Japan Konan Hospital Kobe Hyogo
Japan Umenotsuji Clinic Kochi
Japan Japanese Red Cross Kyoto Daiichi Hospital Kyoto
Japan Tatsuoka Neurology Clinic Kyoto
Japan Shinagawa Strings Clinic Minato Tokyo
Japan Hyogo College of Medicine Nishinomiya Hyogo
Japan Nishinomiya Municipal Central Hospital Nishinomiya Hyogo
Japan Yamaguchi Clinic Nishinomiya Hyogo
Japan Tominaga Hospital Osaka
Japan Sendai Headache and Neurology Clinic Sendai Miyagi
Japan Tokyo Medical University Hospital Shinjuku-ku Tokyo
Japan Tokyo Headache Clinic Tokyo
Mexico Centro de Investigacion Medica Aguascalientes Aguascalientes
Mexico Unidad de Investigación en Salud Chihuahua
Mexico AGNI Research and Assessment S.C. Cuernavaca Morelos
Mexico Hospital Civil Fray Antonio Alcalde Guadalajara Jalisco
Mexico PanAmerican Clinical Research - Guadalajara Guadalajara Jalisco
Mexico Hospital Infantil de Mexico Federico Gomez Mexico City Distrito Federal
Mexico Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Monterrey Nuevo León
Netherlands Canisius-Wilhelmina Ziekenhuis Nijmegen Gelderland
Netherlands Isala, locatie Zwolle Zwolle Overijssel
Puerto Rico Dr. Samuel Sanchez PSC Caguas
Puerto Rico Puerto Rico Health Institute Dorado
Puerto Rico Ponce Medical School Foundation Inc. Ponce
Puerto Rico Wellness clinical Research Vega Baja Vega Baja
Romania Spitalul Clinic de Copii Bra?ov Bra?ov
Romania Delta Health Care Bucharest Bucure?ti
Romania Prof. Dr. Alexandru Obregia Psychiatry Hospital Bucharest Bucure?ti
Romania Constanta County Emergency Clinical Hospital Sf.Ap.Andrei Constanta
Romania Spitalul clinic de urgenta pentru copii Sf. Maria Iasi
Russian Federation First Moscow State Medical University I.M. Sechenov Moscow
Russian Federation Limited Liability Company University Clinic of headaches Moscow Moskva
Russian Federation Saint-Petersburg State Pediatric Medical University Saint Petersburg
Spain Hospital de la Santa Creu i Sant Pau Barcelona Barcelona [Barcelona]
Spain Hospital Universitari Vall d'Hebron Barcelona Barcelona [Barcelona]
Spain Hospital Sant Joan de Déu Esplugues de Llobregat Barcelona [Barcelona]
Spain Hospital General Universitario Gregorio Marañon Madrid
Spain Hospital Universitario 12 de Octubre Madrid
Spain Hospital Universitario Quironsalud Madrid Pozuelo de Alarcon Madrid
Spain Hospital Universitari Parc Tauli Sabadell Barcelona [Barcelona]
Spain Hospital Universitario Virgen Del Rocio Sevilla
Spain Hospital Clinico de Valencia Valencia Valenciana, Comunitat
Spain Hospital Clínico Universitario de Valladolid Valladolid
United Kingdom Great Ormond Street Hospital For Children NHS Foundation Trust Bloomsbury London
United Kingdom Royal Hospital for Sick Children Glagow Scotland
United Kingdom James Paget University Hospital Great Yarmouth Norfolk
United Kingdom Re:Cognition Health - London London London, City Of
United Kingdom University Hospital Lewisham London London, City Of
United States Medical Research Partners Ammon Idaho
United States Children's Hospital Colorado Aurora Colorado
United States ARC Clinical Research at Wilson Parke Austin Texas
United States Pharmasite Research, Inc. Baltimore Maryland
United States Great Lakes Research Group, Inc. Bay City Michigan
United States Northwest Clinical Research Center Bellevue Washington
United States Central Research Associates Birmingham Alabama
United States Qualmedica Research, LLC Bowling Green Kentucky
United States Minneapolis Clinic of Neurology - Burnsville Office Burnsville Minnesota
United States Core Healthcare Group Cerritos California
United States Chicago Headache Center and Research Institute Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Headache Center of Hope Cincinnati Ohio
United States Colorado Springs Neurological Associates Colorado Springs Colorado
United States Driscoll Children's Hospital Corpus Christi Texas
United States Velocity Clinical Research, Providence East Greenwich Rhode Island
United States Michigan State University East Lansing Michigan
United States Qualmedica Research, LLC Evansville Indiana
United States Core Clinical Research Everett Washington
United States Pine Street Pediatrics Exeter California
United States Fort Wayne Neurological Center - West Fort Wayne Indiana
United States Tribe Clinical Research, LLC Greenville South Carolina
United States St. Alexius Medical Center Hoffman Estates Illinois
United States Hawaii Pacific Neuroscience Honolulu Hawaii
United States Pain and Headache Centers of Texas Houston Texas
United States Marshall Medical Center Huntington West Virginia
United States Rehabilitation & Neurological Services Huntsville Alabama
United States Sun Valley Research Center Imperial California
United States Josephson Wallack Munshower Neurology, PC Indianapolis Indiana
United States Clinical Neuroscience Solutions, Inc. dba CNS Healthcare Jacksonville Florida
United States Wolfson Children's Hospital Jacksonville Florida
United States Children's Mercy Hospital Kansas City Missouri
United States Frontier Clinical Research Kingwood West Virginia
United States Alliance for Multispecialty Research, LLC Layton Utah
United States University of Kentucky Chandler Medical Center Lexington Kentucky
United States Arkansas Children's Little Rock Arkansas
United States Miller Children's & Women's Hospital Long Beach Long Beach California
United States Sensa Health Los Angeles California
United States St Luke's Meridian Medical Center Meridian Idaho
United States Velocity Clinical Research, Boise Meridian Idaho
United States ActivMed Practices and Research Methuen Massachusetts
United States Biotech Pharmaceutical Group Miami Florida
United States Ezy Medical Research Miami Florida
United States New Horizon Research Center Miami Florida
United States University of Miami Don Suffer Clinical Research Building Miami Florida
United States Monroe Biomedical Research Monroe North Carolina
United States Chicago Headache Center and Research Institute - Naperville Naperville Illinois
United States Yale University School of Medicine New Haven Connecticut
United States Children's Hospital New Orleans New Orleans Louisiana
United States Velocity Clinical Research - New Orleans New Orleans Louisiana
United States Suncoast Clinical Research, Inc. New Port Richey Florida
United States Deaconess Clinic - Gateway Health Center Newburgh Indiana
United States Sensible Healthcare, LLC Ocoee Florida
United States IPS Research Company Oklahoma City Oklahoma
United States Orange County Research Institute - Ontario Ontario California
United States Qualmedica Research, LLC Owensboro Kentucky
United States Avanza Medical Research Center Pensacola Florida
United States Phoenix Children's Hospital Phoenix Arizona
United States Xenoscience Phoenix Arizona
United States Oregon Health and Science University Portland Oregon
United States Medical Research Partners - Providence Providence Utah
United States SKY Clinical Research Network Group Ridgeland Mississippi
United States Medical Center for Clinical Research San Diego California
United States Meridian Clinical Research, LLC Savannah Georgia
United States Frontier Clinical Research, LLC Scottdale Pennsylvania
United States Perseverance Research Center Scottsdale Arizona
United States Seattle Children's Hospital Seattle Washington
United States Seattle Clinical Research Center Seattle Washington
United States Frontier Clinical Research, LLC Smithfield Pennsylvania
United States Clinvest Research LLC Springfield Missouri
United States Ki Health Partners, LLc, dba New England Institute for Clinical Research Stamford Connecticut
United States Accellacare - Piedmont Statesville North Carolina
United States MultiCare Health System Tacoma Washington
United States ForCare Clinical Research Tampa Florida
United States USF Health Tampa Florida
United States Center for Neurosciences Tucson Arizona
United States Rophe Adult and Pediatric Medicine/SKYCRNG Union City Georgia
United States MedVadis Research Corporation Waltham Massachusetts
United States Children's National Medical Center Washington District of Columbia
United States ClinPoint Trials Waxahachie Texas
United States Integrated Clinical Trial Services, Inc. West Des Moines Iowa
United States Palm Beach Neurology West Palm Beach Florida
United States Alliance for Multispecialty Research, LLC Wichita Kansas
United States Pediatric Neurology P.A. Winter Park Florida
United States New England Regional headache Center, Inc Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

United States,  Belgium,  France,  Germany,  India,  Italy,  Japan,  Mexico,  Netherlands,  Puerto Rico,  Romania,  Russian Federation,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Pain Freedom (High Dose) Percentage of Participants with Pain Freedom (High Dose) 2 Hours Postdose
Secondary Percentage of Participants with Pain Freedom (Mid Dose) Percentage of Participants with Pain Freedom (Mid Dose) 2 Hours Postdose
Secondary Percentage of Participants with Pain Freedom (Low Dose) Percentage of Participants with Pain Freedom (Low Dose) 2 Hours Postdose
Secondary Percentage of Participants with Pain Freedom (Age Sub-Groups) Percentage of Participants with Pain Freedom (Age Sub-Groups) 2 Hours Postdose
Secondary Percentage of Participants with Pain Relief Percentage of Participants with Pain Relief 2 Hours Postdose
Secondary Percentage of Participants Most Bothersome Symptom (MBS)-Free Percentage of Participants MBS-Free 2 Hours Postdose
Secondary Percentage of Participants Nausea-Free Percentage of Participants Nausea-Free 2 Hours Postdose
Secondary Percentage of Participants Photophobia-Free Percentage of Participants Photophobia-Free 2 Hours Postdose
Secondary Percentage of Participants Phonophobia-Free Percentage of Participants Phonophobia-Free 2 Hours Postdose
Secondary Percentage of Participants with Sustained Pain Freedom Percentage of Participants with Sustained Pain Freedom 24 Hours Postdose
Secondary Percentage of Participants with Sustained Pain Freedom Percentage of Participants with Sustained Pain Freedom 48 Hours Postdose
Secondary Percentage of Participants Using Additional Medication for Migraine Percentage of Participants Using Additional Medication for Migraine 24 Hours Postdose
Secondary Percentage of Participants Using Additional Medication for Migraine Percentage of Participants Using Additional Medication for Migraine 48 Hours Postdose
Secondary Degree of Migraine Interference in Normal Activities: Percentage of Participants with a Rating of 0 ("Not at All"), 1 ("a Little"), 2 ("a Lot"), or 3 ("Completely") Degree of Migraine Interference in Normal Activities: Percentage of Participants with a Rating of 0 ("Not at All"), 1 ("a Little"), 2 ("a Lot"), or 3 ("Completely") 2 Hours Postdose
Secondary Acceptability of the Formulation: Percentage of Participants with a Rating of "Very Easy," "Easy," "Neither Easy nor Hard," "Hard," or "Very Hard" Acceptability of the Formulation: Percentage of Participants with a Rating of "Very Easy," "Easy," "Neither Easy nor Hard," "Hard," or "Very Hard" 24 Hours Postdose
See also
  Status Clinical Trial Phase
Completed NCT05525611 - Cabergoline as a Preventive Treatment for Chronic Migraine N/A
Completed NCT06192173 - Patent Foramen Ovale Closure in Migraine
Recruiting NCT03832998 - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine Phase 3
Enrolling by invitation NCT04196933 - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Completed NCT06304675 - Manageable Environmental Factors in Migraine
Completed NCT04084314 - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Phase 4
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Completed NCT04179474 - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Phase 1
Recruiting NCT04603976 - Registry for Migraine - Clinical Core Phase 4
Completed NCT03597529 - CHOCOlate MeLatonin for AdolescenT MigrainE Phase 2
Completed NCT04197349 - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman Phase 1
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting NCT05064371 - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan Phase 3
Suspended NCT04069572 - Vibratory Stimulation for the Treatment of Chronic Pain N/A
Not yet recruiting NCT04859374 - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach N/A
Not yet recruiting NCT03083860 - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions. N/A
Completed NCT02905227 - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder Phase 1
Enrolling by invitation NCT02532023 - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Phase 4
Completed NCT02108678 - One-Day Intervention for Depression and Impairment in Migraine Patients N/A